Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial - PubMed (original) (raw)
Clinical Trial
Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial
Michael J Fine et al. Am J Med. 2003.
Abstract
Purpose: Patients with pneumonia often remain hospitalized after they are stable clinically, and the duration of intravenous antibiotic therapy is a rate-limiting step for discharge. The purpose of this study was to determine whether implementation of an evidence-based guideline would reduce the duration of intravenous antibiotic therapy and length of stay for patients hospitalized with pneumonia.
Methods: In a seven-site, cluster randomized clinical trial, we enrolled 325 control and 283 intervention patients who were admitted by one of 116 physician groups. Within site, physician groups were assigned randomly to receive a practice guideline alone (control arm) or a practice guideline that was implemented using a multifaceted strategy (intervention arm). The effectiveness of guideline implementation was measured by the duration of intravenous antibiotic therapy and length of stay; differences in the rates of discontinuation and hospital discharge were assessed with proportional hazards models. Medical outcomes were assessed at 30 days.
Results: Intravenous antibiotic therapy was discontinued somewhat more quickly in the intervention group (hazard ratio [HR] =1.23; 95% confidence interval [CI]: 1.00 to 1.52; P = 0.06) than in the control group. Intervention patients were discharged more quickly, but the difference was not statistically significant (HR = 1.16; 95% CI: 0.97 to 1.38; P = 0.11). Fewer intervention (55% [157/283]) than control (63% [206/325]) patients had medical complications during the index hospitalization (P = 0.04), with no differences in other medical outcomes, including mortality, rehospitalization, and return to usual activities, between treatment arms.
Conclusions: The multifaceted guideline implementation strategy resulted in a slight reduction in the duration of intravenous antibiotic therapy and a nonsignificant reduction in length of stay, without affecting patient outcomes.
Comment in
- Making evidence-based practice improvement more than a comforting sentiment.
Matchar DB, Patwardhan MB, Samsa GP. Matchar DB, et al. Am J Med. 2003 Oct 1;115(5):407-9. doi: 10.1016/j.amjmed.2003.08.003. Am J Med. 2003. PMID: 14553879 No abstract available.
Similar articles
- Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
Carratalà J, Garcia-Vidal C, Ortega L, Fernández-Sabé N, Clemente M, Albero G, López M, Castellsagué X, Dorca J, Verdaguer R, Martínez-Montauti J, Manresa F, Gudiol F. Carratalà J, et al. Arch Intern Med. 2012 Jun 25;172(12):922-8. doi: 10.1001/archinternmed.2012.1690. Arch Intern Med. 2012. PMID: 22732747 Clinical Trial. - Implementation of an inpatient management and discharge strategy for patients with community-acquired pneumonia.
Stone RA, Mor MK, Lave JR, Hough LJ, Fine MJ. Stone RA, et al. Am J Manag Care. 2005 Aug;11(8):491-9. Am J Manag Care. 2005. PMID: 16095435 Clinical Trial. - Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.
Lee JS, Giesler DL, Gellad WF, Fine MJ. Lee JS, et al. JAMA. 2016 Feb 9;315(6):593-602. doi: 10.1001/jama.2016.0115. JAMA. 2016. PMID: 26864413 Review. - Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.
Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L, Leibovici L. Robenshtok E, et al. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004418. doi: 10.1002/14651858.CD004418.pub3. Cochrane Database Syst Rev. 2008. PMID: 18254049 Updated. Review.
Cited by
- A five-year quasi-experimental study to evaluate the impact of empiric antibiotic order sets on antibiotic use metrics among hospitalized adult patients.
Kufel WD, Steele JM, Mahapatra R, Brodey MV, Wang D, Paolino KM, Suits P, Empey DW, Thomas SJ. Kufel WD, et al. Infect Control Hosp Epidemiol. 2024 May;45(5):609-617. doi: 10.1017/ice.2023.293. Epub 2024 Jan 25. Infect Control Hosp Epidemiol. 2024. PMID: 38268340 Free PMC article. - Does Pneumococcal Vaccination Have an Effect on Hospital Costs?
Şimşek Veske N, Uslu Ö, Oruç Ö, Altın S, Yalnız E, Karakurt Z, Bolat E, Kul S, Kılınç O, Sayıner A. Şimşek Veske N, et al. Thorac Res Pract. 2023 May;24(3):165-169. doi: 10.5152/ThoracResPract.2023.22171. Thorac Res Pract. 2023. PMID: 37503619 Free PMC article. - Acute Coronary Syndrome, Stroke, and Mortality after Community-Acquired Pneumonia: Systematic Review and Meta-Analysis.
Meregildo-Rodriguez ED, Asmat-Rubio MG, Rojas-Benites MJ, Vásquez-Tirado GA. Meregildo-Rodriguez ED, et al. J Clin Med. 2023 Mar 29;12(7):2577. doi: 10.3390/jcm12072577. J Clin Med. 2023. PMID: 37048661 Free PMC article. Review. - Costs of management of acute respiratory infections in older adults: A systematic review and meta-analysis.
Zhang S, Wahi-Singh P, Wahi-Singh B, Chisholm A, Keeling P, Nair H; RESCEU Investigators. Zhang S, et al. J Glob Health. 2022 Nov 8;12:04096. doi: 10.7189/jogh.12.04096. J Glob Health. 2022. PMID: 36342670 Free PMC article. - The challenges of keeping clinicians unaware of their participation in a national, cluster-randomised, implementation trial.
Kuo J, Woodall S, Harding J, Crowther C, Alsweiler J. Kuo J, et al. BMC Med Ethics. 2022 May 30;23(1):55. doi: 10.1186/s12910-022-00794-9. BMC Med Ethics. 2022. PMID: 35637453 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical